Classical- and bioconjugate vaccines: comparison of the structural properties and immunological response
- 18 August 2022
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 78, 102235
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 34 references indexed in Scilit:
- Conjugate-like immunogens produced as protein capsular matrix vaccinesProceedings of the National Academy of Sciences, 2015
- Glycoconjugate vaccines: an updateExpert Opinion on Biological Therapy, 2014
- Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machineryFrontiers in Microbiology, 2014
- Prevention of Staphylococcus aureus Infections by Glycoprotein Vaccines Synthesized in Escherichia coliThe Journal of Infectious Diseases, 2013
- Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunityProceedings of the National Academy of Sciences, 2013
- Exploitation of bacterialN-linked glycosylation to develop a novel recombinant glycoconjugate vaccine againstFrancisella tularensisOpen Biology, 2013
- Glyconanoparticles as multifunctional and multimodal carbohydrate systemsChemical Society Reviews, 2013
- Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine componentGlycoconjugate Journal, 2012
- Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine designJournal of Medical Microbiology, 2012
- Preparation of bacterial polysaccharide–protein conjugates: Analytical and manufacturing challengesVaccine, 2009